Year: 2014
Type: article
Abstract: In hepatology, hepatocellular carcinoma (HCC), not outer space, is the final frontier (sorry, Star Trek fans, https://www.youtube.com/watch?v=S6R3MiAv9ac), given its extremely heterogeneous molecular pathogenesis, dismal prognosis and limited treatment options [1]. Treatment of this neoplasm remains a huge unmet need with no major successes imminent, in contrast to the recent transformative progress in HCV antivirals, and the heightened prospects for antifibrotic therapies. Two articles, by Perra et al.
Source: Journal of Hepatology
Author: Scott L. Friedman
Institution: Icahn School of Medicine at Mount Sinai
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,500
OpenAlex ID: W2159408118